Ratos (RATO) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
17 Jul, 2026Executive summary
Q2 2026 delivered 3.4% organic growth, adjusted EBITA up 14% to SEK 988m, and margin at 17.3%.
Nearly all portfolio companies improved, notably Diab and Speed; EPS up 36% year-over-year.
Strong cash flow and cash conversion above 100%, supported by M&A insurance proceeds and Sentia sell-down.
Continued execution of the 2030 strategy, including portfolio focus, divestments, and add-on acquisitions.
Significant deleveraging, with net debt/EBITDA reduced to 1x, below the target range.
Financial highlights
Net sales reached SEK 5,703m in Q2 2026 (+2% year-over-year); adjusted EBITA SEK 988m (+14%), margin 17.3%.
Adjusted EPS up 36% to SEK 1.97; diluted EPS SEK 3.15 in Q2.
Cash flow from operating activities up 42% to SEK 1,519m in Q2; cash conversion above 100%.
ROCE at 7.3%, with Diab at 14.8%, HL Display at 20.3%, and TFS at 16.9%.
Reported tax rate at 12%, below normalized range of 17%-19%.
Outlook and guidance
Focus remains on sustaining profitable, capital-efficient growth through organic initiatives and strategic add-ons.
Ongoing divestment of non-core companies and continued investment in core platforms.
Portfolio companies expected to benefit from high activity in defense, industrial, and energy sectors.
Latest events from Ratos
- Adjusted EBITDA/EBITA up 32% with strong order intake and Plantasjen turnaround.RATO
Q1 20259 Jul 2026 - Earnings and cash flow rose despite lower sales, aided by efficiency and one-off gains.RATO
Q3 20258 Jul 2026 - Adjusted EBITA/EBITDA rose 21% on 3.4% organic growth, with a new strategy and strong liquidity.RATO
Q1 20264 May 2026 - Adjusted EBITA rose 17% to SEK 1,931m, with improved leverage and major restructuring.RATO
Q4 20254 Mar 2026 - Earnings and margins improved despite 9% lower sales, with strong order intake and cash flow.RATO
Q2 20243 Feb 2026 - Strong cash flow and stable earnings offset sales decline amid major restructuring.RATO
Q3 202419 Jan 2026 - Adjusted EBITA rose, but non-recurring items from Plantasjen led to lower reported profit.RATO
Q4 202423 Dec 2025 - Margin expansion and major capital gains achieved amid challenging market conditions.RATO
Q2 202516 Nov 2025